Radioligand Therapy (RLT) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Radioligand Therapy (RLT) Market Trends and Insights

Precision Oncology and Theranostic Adoption

The radioligand therapy market is supported by the closer use of companion diagnostics and targeted treatment, because both parts of care are planned around the same biological marker. A PSMA PET scan can identify eligible patients, show the distribution of disease, and help predict therapeutic response before treatment begins. This paired model shortens treatment selection, helps clinicians avoid treatment in unsuitable patients, and can reduce clinical attrition. FDA approvals for gallium-68 PSMA PET agents created a reimbursement precedent for related therapeutic use and lowered a practical access barrier. Radiology departments therefore have a larger role in treatment access and hospital procurement decisions, rather than serving only a diagnostic function. SSTR2 programs for neuroendocrine tumors and emerging FAP imaging programs show that this paired diagnostic and therapy approach extends beyond PSMA.

Label Expansion and Earlier-Line Treatment Use

Regulatory label extensions are expanding the treated population in the radioligand therapy market by moving approved therapies into earlier care settings. Each shift to an earlier treatment line can increase the eligible patient group by 2 to 3 times, which gives label decisions outsized commercial importance. The FDA approved Pluvicto in March 2025 for post-ARPI, pre-taxane mCRPC, opening a patient group 75% larger than the earlier post-taxane setting. Novartis anticipates a Q3 2026 FDA decision for Pluvicto in mHSPC based on the PSMAddition trial. Lutathera also gained from earlier-line use in approved GEP-NET settings in the United States and Japan during 2025, together with a pediatric indication. These repeat approval pathways let established products use the same chemistry, manufacturing base, and clinical network across more treatment settings.

Rising Cancer Burden and Aging Population

Cancer incidence is increasing the long-term treatment pool for the radioligand therapy market, particularly for tumor types with a strong relationship to older age. Cancer caused nearly 10 million deaths globally in 2024. Prostate cancer recorded 1.5 million new diagnoses in 2024 and was the most commonly diagnosed cancer among men in 118 of 185 countries. Global cancer incidence reached 19.5 million new cases in 2024 and is expected to reach 35 million annual cases by 2050 as populations age and urbanize. These patterns enlarge the eligible population for PSMA-targeted and somatostatin receptor-targeted therapies, which treat cancers linked to age-related incidence. GEP-NET detection is also rising as molecular imaging becomes more available, expanding diagnosed incidence beyond demographic growth alone.

Increasing Radioisotope and RLT Manufacturing Capacity

Manufacturing expansion is a near-term requirement for the radioligand therapy market because isotope supply must match tight production, transport, and treatment windows. Kinectrics commissioned 4 EMIS units in Toronto in September 2025, lifting annual Yb-176 production above 500 grams and enabling material for more than 150,000 patient treatments each year^{[1]Kinectrics and BWX Technologies, “Kinectrics Significantly Increases Isotope Production Capacity,” BWX Technologies Investor Relations, investors.bwxt.com}. The company is also building a 26,000-square-foot facility to support further scale-up of precursor supply. Novartis is investing USD 23 billion in United States manufacturing over 5 years, including sites planned for Denton, Texas, in 2028 and Winter Park, Florida, in 2029. Its Zhejiang facility in China represents a USD 84.6 million investment and is targeted for commissioning by the end of 2026. These projects respond to the central operational challenge of preparing and delivering sufficient doses before isotope decay reduces their usability.

Therapeutic Radioisotope Supply Constraints

The radioligand therapy market faces a continuing mismatch between growing demand and the time needed to increase isotope output. Reactor-based lutetium-177 depends on a limited number of production facilities, so disruption at one site can affect supply chains across several markets. Laurentis Energy Partners plans to begin commercial lutetium-177 production at Ontario Power Generation’s Darlington Nuclear Generating Station in 2027. The facility is designed to supply 3 million doses, or treatment for 500,000 patients, annually. Actinium-225 availability is even more limited, which may restrict BMS-RayzeBio and AstraZeneca-Fusion programs despite favorable clinical results. Eden Radioisotopes submitted a 2026 NRC permit application for a United States lutetium-177 facility, but reactor projects require multiyear development and commissioning.

Specialized Workforce and Treatment-Center Capacity Shortages

Workforce limitations continue to constrain treatment capacity in the radioligand therapy market even where clinical demand and isotope supply are available. An EANM survey published in 2026 found open positions in more than 80% of European nuclear medicine departments, with shortages in technologists, radiographers, and physicians. The EANM reported 1 nuclear medicine physician per 50 RLT administrations and 1 medical physicist per 138 administrations, limiting rapid expansion without concurrent training^{[2]European Association of Nuclear Medicine, “Building Readiness for Nuclear Medicine: EU Policy Symposium Report,” European Association of Nuclear Medicine, eanm.org}. A scientific review also found that qualified personnel remain insufficient for comprehensive theranostics operations, including in high-income countries. The shortage is more severe in low- and middle-income countries that represent future expansion areas. The EANM RLT Academy and the SNMMI center accreditation program address the gap, but training capacity has not matched demand.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Pluvicto Leads, but Generic Entry into Lutathera Reshapes the Revenue Base

Pluvicto held 45.31% of the product segment in 2025. Its expanding indication set and demand in United States pre-taxane mCRPC supported this position. Pluvicto sales reached USD 1,293 million in H1 2026, 57% above the prior-year period in constant currency. The March 2025 label expansion and growing access outside the United States supported sales. Lutathera is the fastest-growing product, with a 15.58% CAGR forecast from 2026 to 2031.

Lutathera generated USD 816 million in 2025, supported by pediatric approval and earlier-line use in the United States and Japan. Xofigo treats bone-metastatic CRPC through an alpha-emitting mechanism and does not require a companion diagnostic. Lantheus received FDA tentative approval for PNT2003, a radioequivalent of Lutathera, in March 2026. ITM-11 had an FDA PDUFA date of August 28, 2026, adding competitive pressure. Actinium-225 conjugates, lead-212 agents, and copper-64 theranostics will shape the commercial cycle beyond 2028.

By Target: PSMA Dominates; FAP's Pan-Tumor Reach Opens a Long-Horizon Opportunity

PSMA-targeted agents accounted for 58.44% of the target segment in 2025. Pluvicto’s commercial scale and established companion imaging infrastructure supported this position. SSTR remains central to GEP-NET treatment and lower per-cycle costs could increase treatment volumes. FAP is expressed in more than 90% of epithelial malignancies and has potential across multiple tumor types. Earlier FAPI therapeutics showed limited efficacy because tumor retention was short.

Cyclic peptide and albumin-binder modifications are improving dosimetry in active Phase 1 and Phase 2 studies. Eli Lilly’s Point Biopharma, Telix Pharmaceuticals, and Novartis with AAA614 are active FAP developers. GRPR can address early-stage prostate and breast cancer when PSMA expression is insufficient. Novartis’s AAA817, an actinium-225-PSMA-617 compound, targets post-lutetium-177 mCRPC. Sequential use of lutetium-177 and actinium-225 could extend treatment options and revenue per patient.

By Indication: GEP-NETs Accelerate Fastest as the Perimeter Extends into New Tumor Types

Prostate cancer held 55.24% of the indication segment in 2025. GEP-NETs has the highest forecast CAGR at 18.22% from 2026 to 2031. Improved SSTR PET detection, wider PRRT familiarity, and lower costs from generics support GEP-NET treatment growth. Prostate cancer remains the core revenue indication in the radioligand therapy market. The anticipated Q3 2026 FDA decision for Pluvicto in mHSPC could expand the treatable population by 75% against the current mCRPC setting.

Prostate cancer recorded 1.5 million new global cases in 2024. BMS-RayzeBio’s SSTR2-targeted RYZ101 is in Phase 3 for GEP-NETs and SCLC, with data anticipated in 2026^{[3]Bristol-Myers Squibb, “BMS JPM 2026 Investor Presentation,” Bristol-Myers Squibb Investor Relations, bms.com}. SCLC and HCC remain active frontier indications, while breast cancer programs use GRPR and FAP strategies. Telix dosed the first patient in the Phase 3 LUTEON trial for clear cell renal cell carcinoma in July 2026. This program extends antigen-targeted RLT beyond established PSMA and SSTR applications.

By End User: Academic Centers Anchor Revenue; Nuclear Medicine Centers Drive the Access Curve

Tertiary care academic and comprehensive cancer centers represented 58.14% of the end-user segment in 2025. Pluvicto’s REMS program required certified sites with multidisciplinary infrastructure. Academic settings were generally equipped to meet these operational requirements. Specialized nuclear medicine centers are the fastest-growing care setting at a 14.22% CAGR from 2026 to 2031. Standardized protocols and reimbursement for SNMMI-accredited facilities are broadening their treatment role.

Hospitals and specialized clinics offer a sizeable delivery base for the radioligand therapy market. Available trained staff, rather than capital investment, is the main constraint on their expansion. Distributed radiopharmacy networks can reduce dose preparation requirements at individual locations. These networks can support treatment growth after 2027 as local dose access improves. Standardized protocols, accredited centers, and training pipelines can support a wider treatment model.

Geography Analysis

North America held 80.61% of the global market in 2025. Early commercial activity, established nuclear medicine infrastructure, and reimbursement pathways supported its position. The United States has FDA-approved commercial products and a mature PSMA PET network. Novartis is investing USD 23 billion in United States manufacturing over 5 years, including 5 domestic RLT facilities. Canada is developing domestic lutetium-177 capacity through the planned Darlington facility, which is expected to begin commercial operation in 2027.

Europe is the second established region for the radioligand therapy market. EMA approvals for Pluvicto and Lutathera support use across Germany, France, the United Kingdom, Italy, and Spain. Curium announced a EUR 32 million investment (USD 36.5 million), at its Saclay facility in June 2026 for a European lutetium-177 PSMA-I&T production line. Reimbursement differences across EU member states continue to limit wider use outside established academic programs.

Asia-Pacific is the fastest-growing region, with a 15.85% CAGR forecast for 2026 to 2031. China approved Pluvicto in late 2025, its first licensed PSMA-targeted radioligand treatment. Novartis is constructing a Zhejiang facility at CNY 600 million (USD 84.6 million), for commissioning by the end of 2026. Japan is reviewing Telix’s Illuccix application after Phase 3 enrollment finished in July 2026. Australia has approved Pluvicto, while GCC and Brazilian academic investment could support access in the Middle East, Africa, and South America from 2028 to 2031.